Ventilation Heterogeneity Prior to Lung Resection
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04191174 |
Recruitment Status :
Enrolling by invitation
First Posted : December 9, 2019
Last Update Posted : September 10, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Lung Cancer | Other: Hyperpolarized 129Xe MRI Other: Technegas V SPECT Other: Sputum Induction |
Study Type : | Observational |
Estimated Enrollment : | 115 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Official Title: | Prevalence and Clinical Relevance of Ventilation Heterogeneity and Luminal Cellular Inflammation in Lung Cancer Patients Prior to Lung Resection |
Actual Study Start Date : | January 6, 2020 |
Estimated Primary Completion Date : | July 1, 2022 |
Estimated Study Completion Date : | July 1, 2022 |

Group/Cohort | Intervention/treatment |
---|---|
Adults undergoing lung resection for lung cancer |
Other: Hyperpolarized 129Xe MRI
Hyperpolarized 129Xe MRI to evaluate ventilation heterogeneity Other: Technegas V SPECT Technegas V SPECT to evaluate ventilation heterogeneity Other: Sputum Induction Sputum induction to evaluate luminal cellular inflammation |
- Abnormal ventilation heterogeneity assessed by Technegas V SPECT [ Time Frame: Baseline ]Proportion of patients with abnormal ventilation heterogeneity, assessed by Technegas V SPECT, prior to lung resection for lung cancer.
- Abnormal ventilation heterogeneity assessed by 129Xe MRI [ Time Frame: Baseline ]Proportion of patients with abnormal ventilation heterogeneity, assessed by 129Xe MRI, prior to lung resection for lung cancer.
- Technegas V SPECT ventilation heterogeneity and luminal cellular inflammation [ Time Frame: Baseline ]Proportion of patients with preoperative luminal cellular inflammation in the preoperative ventilation heterogeneity normal and abnormal groups, assessed by Technegas V SPECT.
- 129Xe MRI ventilation heterogeneity and luminal cellular inflammation [ Time Frame: Baseline ]Proportion of patients with preoperative luminal cellular inflammation in the preoperative ventilation heterogeneity normal and abnormal groups, assessed by 129Xe MRI.
- Incidence of post-operative pulmonary complications (PPC): Technegas V SPECT ventilation heterogeneity [ Time Frame: up to 4 weeks ]Difference in incidence of PPC and related impact measures in preoperative ventilation heterogeneity normal and abnormal patients, assessed by Technegas V SPECT
- Incidence of PPC: 129Xe MRI ventilation heterogeneity [ Time Frame: up to 4 weeks ]Difference in incidence of PPC and related impact measures in preoperative ventilation heterogeneity normal and abnormal patients, assessed by 129Xe MRI.
- Incidence of PPC: Technegas V SPECT ventilation heterogeneity and luminal cellular inflammation [ Time Frame: up to 4 weeks ]Difference in incidence of PPC and related impact measures in preoperative ventilation heterogeneity abnormal patients, assessed by Technegas V SPECT, with and without preoperative luminal cellular inflammation.
- Incidence of PPC: 129Xe MRI ventilation heterogeneity and luminal cellular inflammation [ Time Frame: up to 4 weeks ]Difference in incidence of PPC and related impact measures in preoperative ventilation heterogeneity abnormal patients, assessed by 129Xe MRI, with and without preoperative luminal cellular inflammation.
- Correlation between ventilation heterogeneity quantified by Technegas V SPECT and 129Xe MRI [ Time Frame: Baseline ]Univariate correlation between preoperative ventilation heterogeneity quantified by Technegas V SPECT and 129Xe MRI.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Undergoing lung resection for lung cancer at St. Joseph's Healthcare (Hamilton, Ontario) in accordance with British Thoracic Society guidelines.
- Males and females ≥ 18 years of age.
- Able and willing to provide written informed consent.
- Able and willing to comply with the study protocol.
Exclusion Criteria:
- Previous lung resection surgery.
- Previous chest radiation.
- Patient has an implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples.
- In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia.
- Pregnancy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04191174
Canada, Ontario | |
Firestone Institute for Respiratory Health, Research - St. Joseph's Healthcare | |
Hamilton, Ontario, Canada, L8N 4A6 |
Principal Investigator: | Parameswaran Nair, MD, PhD | McMaster University |
Responsible Party: | McMaster University |
ClinicalTrials.gov Identifier: | NCT04191174 |
Other Study ID Numbers: |
FIRH_Xe004 |
First Posted: | December 9, 2019 Key Record Dates |
Last Update Posted: | September 10, 2021 |
Last Verified: | September 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
lung cancer lung resection ventilation heterogeneity |
Technegas V SPECT hyperpolarized 129Xe MRI airway inflammation |
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases |